ArticleMalaria journal2026
Simultaneous serological assessment of vector and pathogen exposure to support intervention monitoring and understand host-vector interactions.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Assessing the presence and magnitude of antibodies to pathogens and vector-saliva, i.e., serosurveillance, is a valuable tool to determine actual exposure of individuals to arthropod vectors and vector-borne pathogens under real life conditions. Antibodies to vector saliva proteins have already demonstrated the potential to serve as biomarkers for exposure to mosquitoes. Since various mosquito species can carry pathogens such as Plasmodia and flaviviruses, positive serological responses to mosquito saliva have been associated with a higher risk of infections in human populations in endemic areas. A recently developed novel high-throughput multiplex assay simultaneously measures antibodies to vector saliva and pathogen-specific antigens as a tool to monitor the efficacy of countermeasures such as repellants and prophylactic drugs in travelers and residents of African malaria-endemic countries. In the current study, this panel was adapted to include vector-specific probes prevalent in Southeast Asia and test samples from serial cross-sectional surveys in Cambodia. The results revealed distinct immune signatures indicative of distinct patterns of host-vector contact, i.e., bite by infected mosquitoes leading to infection or not, or relapse caused by dormant liver-stage parasites. This approach provides a more detailed understanding of exposure dynamics than traditional surveillance methods, while using a single assay. The study establishes the utility of serosurveillance tools for augmenting conventional entomological and serological methods, particularly in low-transmission settings and when rates of infected vectors are low, thus offering a powerful platform for monitoring exposure to vectors and parasites, disease transmission, and evaluating the efficacy of vector control strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.